United States Patent [19]

Keefer et al.

[11] **Patent Number: 5,039,705**

[45] **Date of Patent: Aug. 13, 1991**

[54] **ANTI-HYPERTENSIVE COMPOSITIONS OF SECONDARY AMINE-NITRIC OXIDE ADDUCTS AND USE THEREOF**

[75] Inventors: **Larry K. Keefer**, Bethesda; **David A. Wink**, Frederick; **Tambra M. Dunams**, Frederick; **Joseph A. Hrabie**, Frederick, all of Md.

[73] Assignee: **The United States of America as represented by the Department of Health and Human Services**, Washington, D.C.

[21] Appl. No.: **409,552**

[22] Filed: **Sep. 15, 1989**

[51] **Int. Cl.**[5] **A61K 31/13**; A61K 31/20; A61K 31/195; A61K 31/655

[52] **U.S. Cl.** **514/611**; 514/149; 514/558; 514/563; 514/564; 514/579; 514/610; 514/645

[58] **Field of Search** 514/611, 149, 558, 563, 514/564, 610, 645, 579

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,153,094 10/1984 Reilly 260/576

OTHER PUBLICATIONS

Palmer, Nature 327, 524–526, 1987.
Kruszyna et al. Toxicol. and Applied Pharmacol. 91, 429–438, 1987.
Ignarro, The FASEB Journal 3, 31–36, 1989.
Ignarro et al., J. Pharmacol. & Exper. Therapeutics 218(2), 739–749, 1981.
Drago, "Free Radicals in Inorganic Chemistry", No. 36, Advances in Chemistry Series, Amer. Chem. Soc., Wash. DC, 1962, pp. 143–149.
Drago et al., J. Amer. Chem. Soc. 83, 1819–1822, 1961.
Deluca et al., "Pharmaceutics and Pharmacy Practice" J.B. Lippincott Co., Philadelphia, 1982, 238–250.
Trissel, ASHP, "Handbook on Injectable Drugs" 4th ed; 622–630, 1986.

Primary Examiner—Allen J. Robinson
Attorney, Agent, or Firm—John Bailey; Robert Benson

[57] **ABSTRACT**

This invention concerns anti-hypertensive compositions and a method of lowering blood pressure in mammals. The active component of the compositions is a compound of the formula:



I

wherein R_1 and R_2 are independently chosen from straight chain and branched chain C_1–C_{12} alkyl groups and benzyl, with the proviso that no branch occur on the alpha carbon atom of the alkyl groups; or R_1 and R_2 together with the nitrogen atom they are bonded to form a pyrrolidino, piperidino, piperazino or morpholino group, $M^+$is a pharmaceutically acceptable cation, wherein X is the valence of the cation.

14 Claims, No Drawings